VIPoma pathophysiology: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{VIPoma}} | {{VIPoma}} | ||
{CMG}}{{AE}}{{PSD}} | {{CMG}}{{AE}}{{PSD}} | ||
==Overview== | ==Overview== | ||
Revision as of 13:58, 16 October 2015
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma pathophysiology On the Web |
|
American Roentgen Ray Society Images of VIPoma pathophysiology |
|
Risk calculators and risk factors for VIPoma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Pathophysiology
VIPoma causes cells in the pancreas to produce high levels of a hormone called vasoactive intestinal peptide (VIP). This hormone increases secretions from the intestines and relaxes some of the smooth muscles in the GI system.
The massive amounts of VIP in turn cause profound and chronic watery diarrhea and resultant dehydration, hypokalemia, achlorhydria (hence WDHA-syndrome, or pancreatic cholera syndrome), acidosis, vasodilation (flushing and hypotension), hypercalcemia and hyperglycemia.[1]
Associated Conditions
It may be associated with multiple endocrine neoplasia.
References
- ↑ Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004; 120: 139-61. PMID 15172200